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Background/Aims: In patients with resistant hypertension, renal denervation (RDN) 
studies have mainly focused their outcomes on blood pressure (BP). The aim of this 
study was to evaluate the long-term effect of RDN on neurohormonal profiles, renal 
hemodynamics and sodium excretion in a resting state and during stress induced by 
lower body negative pressure (LBNP).
Materials and methods: This was a single center prospective observational study. 
Norepinephrine, plasma renin activity (PRA), glomerular filtration rate (GFR), renal plasma 
flow (RPF) and sodium excretion were measured in unstimulated conditions (rest) and 
after one hour of LBNP at three different time points: before (M0), one (M1) and twelve 
months (M12) after RDN.
Results: Thirteen patients with resistant hypertension were included. In the resting state, 
no differences were observed in norepinephrine, PRA, sodium excretion and mean BP 
levels after RDN. GFR (78 ± 32 ml/min at M0 vs 66 ± 26 ml/min at M12 (p = 0.012) and 
filtration fraction (22.6 ±5.4% at M0 vs 15.1 ±5.3% at M12 (p = 0.002)) both decreased 
after RDN. During LBNP, the magnitude of the mean BP increase was reduced from +6.8 
± 6.6 mm Hg at M0 to +2.3 ± 1.3 mm Hg at M12 (p = 0.005). The LBNP-induced 
increase in norepinephrine and decrease in GFR and sodium excretion observed before 
RDN were blunted after the procedure.
Conclusion: A decrease in GFR and filtration fraction was observed one year after RDN. 
In addition, our results suggest that RDN blunts not only the norepinephrine but also 
the mean BP, the GFR and the sodium excretion responses to an orthostatic stress one 
year after the intervention.
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intrODuctiOn
Catheter-based radiofrequency ablation of renal sympathetic 
nerves has been developed specifically for the treatment of 
resistant hypertension (1). However, its use remains controversial 
as the enthusiasm generated by the first publications reporting 
substantial reduction in office blood pressure (BP) was tempered 
by the heterogeneity of the BP response and by the results of the 
Symplicity HTN3 trial, which failed to demonstrate a significant 
difference in BP reduction between renal denervation (RDN) and 
a sham procedure (2, 3). Moderate but unpredictable reductions 
in office and ambulatory BP, however, have been demonstrated in 
subsequent controlled trials, which used either a strict standardized 
stepped-care antihypertensive treatment or an off  medication 
design (4, 5).
The rationale for using the sympathetic nervous system (SNS) 
as a therapeutic target is the increased sympathetic tone observed 
in hypertension (6). This is particularly important at the level 
of the kidneys where the SNS contributes to the regulation of 
renin secretion, renal hemodynamic and sodium excretion (7). 
The objective of RDN is to destroy the sympathetic nerves fibers 
surrounding the renal arteries and therefore limit afferent and 
efferent signaling of the renal SNS. The procedure is non-selective 
as both afferent and efferent sympathetic nerves fibers can be 
affected. Today, the extent of renal denervation achieved cannot 
be assessed easily during or after the procedure in humans. The 
efficacy of the intervention has been judged almost exclusively 
on BP reduction, which is a rather indirect and imprecise way 
of assessing the effectiveness of the procedure. Yet office or out-
of-office BP have been used as primary objective in most trials 
(1, 2, 4, 8). Independently of its effect on BP, RDN could affect 
renal plasma flow, renin release and sodium excretion, which are 
directly related to renal SNS activity (7). So far, few clinical studies 
have evaluated the impact of RDN on renal function other than 
estimated glomerular filtration rate (GFR).
In dogs, Di Bona et al have shown that progressive electric 
stimulation of renal sympathetic nerves causes an increase in plasma 
renin activity at low frequency, an increase in renal tubular sodium 
reabsorption at higher frequency and renal vasoconstriction at 
very high frequency (7). We have shown that in humans, kidneys 
react similarly to increasing levels of lower body negative pressure 
(LBNP), leading to similar stepwise increase in peripheral 
norepinephrine release, activity of the renin-angiotensin system, 
renal tubular reabsorption of sodium (9). During LBNP, venous 
blood is pooled in the lower extremities, thereby decreasing central 
venous pressure and unloading cardiopulmonary baroreceptors, 
which induces a reflex activation of the renin-angiotensin-
aldosterone system (RAAS) and the SNS and depending on the 
magnitude of the negative pressure, affect cardiovascular and renal 
function (10, 11). In the present study, we hypothesized that if RDN 
was effective in disrupting the efferent renal sympathetic nervous 
pathway, changes in the plasma renin activity, renal tubular sodium 
excretion and renal plasma flow would be observed after RDN 
either in non-stimulated conditions (resting state) and particularly 
in response to an orthostatic stress induced by LBNP.
Therefore, the objectives of the study were to assess the long-
term effect of RDN on the plasma norepinephrine and renin 
activity profile, renal hemodynamics and sodium excretion in 
standardized non-stimulated conditions and during an orthostatic 
stress induced by LBNP.
MethODs
The study was a single-center prospective observational study. 
The protocol was approved by the local Ethical Committee 
[Commission cantonale d'éthique de la recherche sur l'être 
humain (CER-VD)]. Written informed consent was obtained 
from all participants.
study Population
Patients were eligible for this study if they were referred for 
RDN and were older than 18 years. Patients were excluded 
from the study if they had orthostatic hypotension (positive 
Shellong’s test). The decision to perform RDN was taken by a 
multidisciplinary team including an interventional radiologist, a 
cardiologist and a hypertension specialist. RDN eligibility criteria 
were : (1) resistant hypertension defined as daytime ambulatory 
BP >135/85 mm Hg or nighttime BP >120/70 mm Hg despite 
the use of three antihypertensive drugs [one blocker of the 
renin-angiotensin system, one calcium channel blocker (CCB) 
or one beta blocker if CCB were not tolerated and one diuretic] 
at maximum tolerated doses (2) adequate adherence (>80%) 
to these 3 drugs assessed by the medication event monitoring 
system (MEMS®), (3) no secondary cause of hypertension 
(primary aldosteronism, hypothyroidism, Cushing syndrome, 
pheochromocytoma or renal artery stenosis), (4) estimated GFR 
> 30 ml/min/1.73 m2, (5) a suitable renal artery anatomy without 
extensive calcification (at least one renal artery on each side, renal 
artery main trunk's length >2 cm, renal artery diameter >4 mm). 
Radiofrequency renal denervation was performed under general 
anesthesia by one experienced interventional cardiologist and 
one experienced interventional radiologist using the Symplicity 
Flex catheter (Medtronic, MN, USA) or EnligHTN IV catheter 
(St Jude Medical, St Paul, MN). Both doctors were proctored 
before the initiation of the study. The target number of renal 
artery ablation points was five in each renal artery according 
to initial recommendations from manufacturers. The same 
antihypertensive treatment was continued after RDN. The 
antihypertensive treatment was reduced in case of hypotensive 
symptoms or if office systolic blood pressure was <120 mm Hg. 
Target office BP pressure was <140/90 mm Hg. Patients were seen 
in the outpatient hypertension clinic for screening and one week, 
three months, six months after RDN. Study days (renal clearance 
studies) were performed before RDN (M0), one month (M1) and 
12 months (M12) after RDN. Recruitment started in 2012 and 
the last patient last study day was in May 2015.
Data collection
Patients included in the study were investigated on three separate 
standardized study days (M0, M1 and M12). On the day before 
the study days, a 24 h urine collection to estimate sodium intake 
and a 24 h ambulatory BP measurement (ABPM) with an 
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adequately sized cuff (WatchBP03, Microlife AG, 9443 Widnau, 
Switzerland) were started. BP measurements during ABPM were 
taken every 20 min during the day and every 30 min at night. 
Daytime and nighttime period were defined according to patients' 
diary (bedtime and wakeup time) (12). Patients were studied with 
water and sodium intake ad libitum before the study day. Caffeine 
containing beverages and smoking was prohibited in the 24 h prior 
to the study day. In order to compare study days before and after 
RDN in standardized conditions, antihypertensive therapy was 
fixed to a combination of an angiotensin II receptor blocker and 
a calcium channel blocker in all patients in the morning of the 
study days. All other antihypertensive drugs were stopped 24 h 
before the study day.
On study days (Figure 1), patients were asked to come to the 
clinic at 07.30 am. A venous catheter was inserted in each forearm: 
one for blood sampling and one for inulin (Inustest®, Fresenius 
Kabi Austria GmbH) and para-aminohippuric acid (PAH, Merck 
Sharp & Dhome Corp., USA) infusion. Inulin clearances were 
used to measure glomerular filtration rate (GFR) and PAH 
clearances were used to measure renal plasma flow (RPF). 
Fasting blood glucose was measured to exclude hyperglycemia. 
If patients had diabetes, blood glucose was measured hourly. A 
light breakfast, allowed antihypertensive drugs and an oral water 
load of 5 ml/kg were given, once infusion of PAH and inulin were 
started (08:00 am). Thereafter, 150 ml of water was given hourly 
in order to maintain urine output and facilitate clearance studies. 
After 2 hours of equilibrium period and one hour to stabilise 
urine output, one hour resting clearance study was followed by 
hour of lower body negative pressure (−30 mbar; −22.5 mmHg). 
LBNP was applied with subjects in the supine position with a 
solid plexiglass box sealed tightly just below the iliac crests(9). 
Blood and urine samples were collected at the end of each hour 
during the clearance study. Patients remained supine for the 
study except for voiding, which followed blood sampling. Vital 
signs (BP and heart rate) were measured every 15 min during the 
clearance study (Omron, HEM-907, Omron healthcare Europe 
BV, Scorpius33, 2132 R Hoofddorp, the Netherlands).
Urinary electrolyte excretion rate was calculated as Ux · V and 
clearances (mL/min) using the standard formula Cx = Ux · V/Px, 
where Ux and Px are the urine and plasma concentrations of x 
and V is the urine flow rate in mL/min. The fractional excretions 
were calculated as the clearance of x divided by the GFR. FF was 
calculated by dividing GFR by RPF. Renal vascular resistances 
were calculated as mean BP divided by the renal blood flow, this 
latter being calculated from renal plasma flow and hematocrit. 
BMI was calculated as weight (kilograms) divided by squared 
height (meters squared). Estimated GFR was calculated using 
the CKD-EPI equation (13).
Plasma and urinary inulin and PAH were determined by 
photometry (Autoanalyzer II-Technicon;  Bran and Luebbe, 
Norderstedt, Germany). Endogenous trace lithium, used a 
marker of renal proximal sodium reabsorption, was measured by 
atomic absorption spectrophotometry (14). Plasma renin activity 
was measured by radioimmunoassay of generated concentration 
of angiotensin I using a commercial kit (GammaCoat [125I] 
Plasma Renin Activity Radioimmunoassay Kit, DiaSorin Inc., 
Stillwater, MN, USA), while measurement of aldosterone in the 
blood was performed with a commercial RIA kit (Aldo-Riact; CIS 
Bio International, Yvette. Cedex, France). Plasma catecholamines 
(norepinephrine and epinephrine) were measured using ultra 
high performance liquid chromatography-tandem mass 
spectrometry(15).
To compare the baseline hormonal profile and sodium 
excretion of patients with resistant hypertension, a group of 
Figure 1 |  Study day schedule, which was repeated before renal denervation (M0), one month after renal denervation (M1) and 12 months after renal denervation 
(M12). LBNP, lower body negative pressure; PAH, para-amino hippurate. Infusion of inulin and PAH were used to measure glomerular filtration rate and renal plasma 
flow. LBNP was fixed at −30 mbar for one hour.
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healthy volunteers and a group of obese hypertensive patients 
were used. Both groups had been taking candesartan 16 mg 
po per day for one week and were studied in the same baseline 
study setting.
statistical analysis
Data are expressed as mean ±  standard deviation (SD) for 
normally distributed data and as median and interquartile 
range (IQR) or geometric mean with 95% CI for non- normally 
distributed data. Differences between variables before and after 
LBNP were tested using a paired t-test for normally distributed 
data and using a Wilcoxon matched-pairs signed-rank test for 
non-normally distrusted variable. Resting state PRA between 
resistant hypertensive participants and hypertensive obese or 
healthy participants was compared using a Wilcoxon rank-sum 
test . Resting state variables over the three phases (M0, M1, M12) 
were zero-skewness log or Box-Cox transformed when necessary 
to ensure the variable normality. Changes induced by LBNP over 
phases (M0, M1, M12) were examined using random intercept 
mixed-effect linear regression model with only the phase as 
explanatory variable.
results
Twenty-five out of ninety-six patients referred for RND were 
eligible and underwent the RDN procedure. Two patients 
included in the final analysis reported hypotensive symptoms in 
the week following the procedure and had their antihypertensive 
treatment reduced. One patient developed a pseudo-aneurysm 
of the right femoral artery treated by surgical repair. One patient 
had a microdissection of the right renal artery that was treated 
conservatively. Echodoppler of the right renal artery was normal 
after 24 h. No renal artery stenosis was detected among the patients 
by a systematic screening with a CT angiography after one year. 
Fourteen patients of the twenty-five patients eligible for RDN 
accepted the current study and signed the informed consent. The 
LBNP technique was applied to all but one participant who felt 
uncomfortable in the plexiglas box on the first study day, leaving 13 
patients for the analysis. The Symplicity Flex catheter was used in 
11 patients and the EnligHTN IV catheter in 2 patients. The mean 
number of ablation points in these patients was 5 [interquartile 
range (IQR): 4,5] points of the left renal artery and 5 (IQR: 4;5) 
points on the right renal artery. The total number of ablation 
points was 10 (IQR: 8; 10) points. No hypotension or pre-syncope 
signs or symptoms were noted during the LBNP period. Baseline 
characteristics of the patients are presented in Table 1. No change 
in the use of antihypertensive drugs was apparent between M0 
and M12. When diuretics were grouped, the percentage of use 
was decreased at M1, but not at M12 compared to M0 [p = 0.023 
(overall test), p = 0.012 (M1 vs. M0) and p = 0.790 (M12 vs. M0)].
effects of rDn in standard non-
stimulated conditions
Plasma norepinephrine and epinephrine levels were not different 
before and after renal denervation (Table 2). Both resting state 
PRA and aldosterone were low in these patients. PRA was much 
lower in patients with resistant hypertension than in healthy 
volunteers or in obese patients in the same experimental setting 
(Figure 2). In standard non-stimulated conditions, baseline PRA 
was also similar before and after RDN. Plasma aldosterone levels 
were lower one month after RDN compared to pre-RDN values 
but no difference was seen at 12 months.
taBle 1 | Characteristics ofthe patients before and one year after renal denervation.
characteristics of the patients M0 M1 M12 P (M0 vs M12) 
Number (n) 13 13 13 
Age (y) 56.1 ± 9.9 - - - 
Women (%) 15.4 - - - 
Diabetes (%) 23.1 - - - 
Systolic blood pressure day (mm Hg) 157 ± 23 153 ± 23 146 ± 20 0.23 
Diastolic blood pressure day (mm Hg) 95 ± 12 89 ± 17 91±12 0.46 
Systolic blood pressure night (mm Hg) 140 ± 24 144 ± 27 134 ± 15 0.496 
Diastolic blood pressure night (mm Hg) 85 ± 12 81 ± 15 83 ± 11 0.731 
BMI (Kg/m2) 30.9 ± 6.3 - - 
eGFR (ml/min/1.73m2) 69.5 ± 21.6 74.3 ± 23 65.2 ± 25.3 0.641 
Number of antihypertensive drugs* 4.8 ± 1.8 3.1 ± 1.6 3.7 ± 1.7 0.103 
Angiotensin II receptor blocker (%) 61.5 61.5 69.2 0.68 
Angiotensin converting enzyme inhibitor (%) 23.1 7.7 7.6 0.277 
Thiazide diuretic (%) 61.5 30.7 53.8 0.691 
Loop diuretic (%) 30.8 30.8 38.4 0.68 
Calcium channel blocker (%) 92.3 84.6 84.6 0.539 
Beta-blocker (%) 69.2 53.9 46.2 0.234 
Other antihypertensive (%) 76.9 38.5 61.5 0.395 
Sodium excretion (mmol/24 h) 154 ± 95 190 ± 117 144 ± 21 0.839 
Values are presented as mean (SD) or percentages. –, Not applicable; M0, before renal denervation; M12, 12 months after renal denervation; P, p value; BMI, body mass index; 
eGFR, estimated glomerular filtration rate.
* The daily number of antihypertensive drugs outside the study day at screening and after one year (M12).
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RDN had no effect on resting systolic or diastolic BP  as 
shown in Table  3. Resting heart rate increased from 58 ± 11 
bpm (beats per minute) to 63 ± 11 bpm after one month and 
64 ± 12 bpm 12 months after RDN. Baseline measured GFR but 
not estimated GFR (Table 1) decreased 12 months after RDN. 
RPF tended to increase after RDN. These changes resulted in 
a significant decrease in filtration fraction (FF), especially 12 
months after RDN (Figure 3). Renal vascular resistances also 
tended to decrease after RDN.
The changes in sodium and lithium renal handling are shown 
in Table  4. Compared to pre-denervation conditions, urine 
output and urinary sodium excretion did not change after one 
and twelve months. In contrast, the clearance of endogenous 
lithium decreased twelve months after RDN.
effects of rDn in stimulated conditions
During LBNP, norepinephrine increased before RDN and one 
month after the procedure, but this increase was no longer 
significant 12 months after RDN (Table 2). Epinephrine levels 
also increased during the LBNP period but only before RDN. 
The magnitude of the changes induced by LBNP was, however, 
not different before or after RDN for both epinephrine (+0.08 ± 
0.10 nM at M0, +0.06 ± 0.13 nM at M1 and +0.05 ± 0.12 at M12, 
p = 0.461 overall test) and norepinephrine (+0.25 ± 0.59 nM at 
M0, +0.33 nM at M1 and +0.14 at M12, p = 0.550 overall test). 
LBNP had no effect on PRA but the magnitude of the changes 
induced by LBNP tended to increase with time (−0.32 ± 1.12 
ng/ml/h before RDN vs 0.01 ± 0.17 ng/ml/h after one month vs. 
0.2 ± 0.49 ng/ml/h after 12 months, p = 0.061 (overall test), p = 
0.386 (M1 vs. M0) and p = 0.019 (M12 vs. M0)). LBNP had no 
effect on aldosterone at M1 and M12 and no difference could 
be detected in LBNP-induced changes in aldosterone before and 
after RDN.
LBNP increased SBP and DBP before RDN and one month 
after RDN but not at 12 months (Table 3). The magnitude of the 
changes in mean BP induced by LBNP diminished significantly 
with time as shown in Figure 4. No LBNP-induced heart rate 
changes were detected and there were no difference in the 
magnitude of the changes between baseline and following 
visits. During LBNP, GFR and RPF decreased significantly 
only before RDN. LBNP did not affect filtration fraction at any 
study visit.
Urine output decreased significantly during the LBNP period, 
before as well as 1 and 12 months after RDN (Table  3). LBNP 
induced a reduction of urinary sodium excretion before RDN 
and one month after the procedure but this effect was not seen at 
12 months. The changes in lithium clearance induced by LBNP 
stimulation were similar before and after RDN.
DiscussiOn
This study is the first to focus on the neuro-hormonal, renal 
hemodynamic and sodium handling changes induced by RDN, 
not only in the resting state but also in response to an orthostatic 
stress induced by LBNP. Twelve months after RDN, no changes in 
office and 24 h BP were observed but measured GFR, using inulin 
clearance, was decreased and renal plasma flow increased leading 
to a significant reduction of filtration fraction at one year. The 
increase in norepinephrine induced by LBNP was blunted after 
taBle 2 | Hormones before andafter renal denervation at rest and during LBNP.
Variable Period Before lBnP lBnP P 
Norepinephrine (nM)  M0 1.68 (1.32; 2.13) 1.91 (1.53; 2.40) 0.039 
M1 1.63 (1.30; 2.05) 1.98 (1.66; 2.38) 0.055 
M12 1.81 (1.42; 2.32) 2.02 (1.67; 2.44) 0.279 
mixed model P = 0.666 
M1 vs. M0 P = 0.823 
M12 vs. M0 P = 0.519 
Epinephrine (nM)  M0 0.099 (0.057; 0.171) 0.167 (0.104; 0.266) 0.015 
M1 0.063 (0.033; 0.120) 0.110 (0.061; 0.197) 0.208 
M12 0.095 (0.053; 0.172) 0.110 (0.055; 0.224) 0.624 
mixed model P = 0.342 
M1 vs. M0 P = 0.192 
M12 vs. M0 P = 0.939 
PRA (ng/ml/h)  M0 0.234 (0.095; 0.575) 0.207 (0.102; 0.421) 0.84 
M1 0.279 (0.117; 0.664) 0.291 (0.124; 0.685) 0.885 
M12 0.525 (0.213; 1.30) 0.609 (0.246; 1.51) 0.181 
Mixed model P = 0.236 
M1 vs. M0 P = 0.780 
M12 vs. M0 P = 0.111 
Aldosterone (pg/ml)  M0 83.3 (53.9; 112.7) 72.3 (44.0; 118.8) 0.753 
M1 43.7 (30.6; 62.5) 42.2 (34.0; 53.0) 0.65 
M12 66.5 (37.8; 116.8) 60.6 (35.1; 104.3) 0.162 
Mixed model P = 0.038 
Baseline vs. M1 P = 0.021 
Baseline vs. M12 P = 0.833 
Results are geometric means with 95% confidence interval. PRA, plasma renin activity; M0, before renal denervation; M1, 1 month after renal denervation, M12: 12 months after 
renal denervation
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RDN. This might explain why BP, GFR and RPF were less or not 
sensitive to LBNP after RDN. Regarding renal tubular function 
during orthostatic stress, the sodium reabsorption induced by 
LBNP was also blunted at 12 months. The results from our study 
also confirms that in non-stimulated conditions, patients with 
resistant hypertension have a down-regulated RAAS with a low 
renin activity and a low aldosterone, which is not stimulated 
by LBNP.
BP has been the primary outcome of most of the trials in 
RDN. The absence of effect on baseline BP, whether office or 
ambulatory BP (Tables 1,2), is in line with the SIMPLICITY-3 
trial (2). The small sample size, not powered for ambulatory BP 
in our study, may also explain the heterogeneous BP response, a 
common finding in RDN studies (3). One original observation 
of the present study is  that the BP response to orthostatic stress 
using LBNP is significantly blunted after RDN suggesting an 
impaired hemodynamic reactivity to stress. To our knowledge, 
this effect of renal denervation has never been reported. Using 
a tilt test, Lenski et al. found that in RDN responders, the SBP 
response was decreased in the initial phases of the test (16). This 
observation is in line with ours but one has to mention that in 
our study setting, the orthostatic stress was applied for one hour, 
i.e., much longer than a tilt test. Similarly, the reactivity of BP to 
exercise seems to be affected by RDN, as shown by Ewen et al 
(17). This group demonstrated that at mild to moderate exercise 
intensity, BP response was reduced 6 and 12 month after RDN. 
This blunted BP response to orthostatic stress using the tilt test 
or LBNP and to an exercise stress test suggest that even in the 
absence of marked decrease in BP, RDN has an impact on BP 
regulation and this may explain the decrease in variability of 24 
h BP observed in some studies (18–20).
The use of inulin and PAH clearances allowed us to have a 
precise and absolute evaluation of the impact of RDN on renal 
hemodynamic not only in the resting state but also during 
orthostatic stress. The study is the first to report a decrease 
in measured GFR, not apparent in estimated GFR. So far, 
GFR estimated with the CKD-EPI creatinine based equation 
or with cystatin was not found to decrease after RDN (1, 2, 
4, 21). Increases in estimated GFR has even been reported in 
patients with chronic kidney disease, in particular if BP was 
well controlled after RDN (22, 23). Interestingly, a post-hoc 
analysis of the DENERHTN trial recently reported that the 
degree of abdominal calcifications was associated with the BP 
and the estimated GFR response to RDN (24). The decrease in 
measured GFR using the gold standard method is important 
and may raise concerns about a possible unfavorable effect 
on renal function. It should be interpreted in the light of the 
increase in renal plasma flow, resulting in a significant decrease 
in filtration fraction 12 months after RDN and the decrease 
in calculated renal vascular resistance. The decrease in renal 
vascular resistance is consistent with the results of Ott et al., who 
also found a renal vasodilation after RDN using MRI with arterial 
spin labeling to measure renal perfusion.(21) Using Doppler 
ultrasound, Mahfoud et al. showed that the renal resistive 
index decreased three and six months after RDN in 88 patients. 
Patients with resistant hypertension from our study appear to 
have an increased renal sensitivity to orthostatic stress before 
renal denervation as significant decreases in GFR and RPF were 
observed during LBNP. This effect was also observed in healthy 
volunteers taking an angiotensin receptor blocker but not with 
a placebo(25). This vasoconstrictor effect of LBNP was blunted 
after RDN, pointing to a change in the renal autoregulation of 
blood flow. This change could be secondary myogenic or tubulo-
glomerular feedback mechanisms that may also affect the renal 
sodium excretion. The absence of compensatory hemodynamic 
mechanisms during stress observed after RDN could raise safety 
issues, particularly with severe hypotension, such as following 
acute hemorrhage (26).
In our study, resting state sodium excretion was not affected by 
RDN, although clearance of endogenous lithium was decreased 
12 months after RDN, which suggests an increased reabsorption 
of sodium in the proximal tubule. This effect may be the 
consequence of the decrease in filtration fraction. It is unlikely 
to be attributable to the use of diuretics, as they were prohibited 
on the study day. Yet, one cannot exclude that it represents a 
compensatory mechanism after withdrawal of diuretics(27). 
Moreover, the use of diuretics after renal denervation did not 
increase with time, but rather decreased shortly after RDN (M1). 
Figure 2 |  Norepinephrine (NE), Plasma renin activity (PRA) and twenty-four hour sodium excretion (UNa 24H) in healthy normotensive volunteers (HV, N = 20), 
obese normotensive and hypertensive patients (OB, N = 20), and in hypertensive resistant patients (RH, N = 13). NE, PRA and UNa 24H were measured in the 
same experimental setting. Data are expressed as median and interquartile range, minimum and maximum (a) and mean ± SD (B).
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Interestingly, the orthostatic stress induced an anti-natriuresis 
before RDN but not after denervation. Indeed, the anti-
natriuretic effect of LBNP found before RDN and at M1 was not 
found 12 months after RDN, suggesting that the ability to retain 
sodium, when kidneys are stressed, is also blunted after RDN. 
This effect parallels the blunted renal hemodynamics response 
to LBNP, which could be one of the explanatory mechanism. A 
direct inhibitory effect of RDN on the alpha-1 adrenoreceptor 
mediated sodium retention could be another explanation (7). 
However, the decreased lithium clearance seen 12 months after 
RDN, suggesting a proximal sodium retention, goes against this 
mechanism. Finally, other vasoactive peptides interacting with 
the SNS such as endothelin could have influenced the renal 
hemodynamic or natriuretic response (28). The clinical impact 
of this observation, suggesting that the pressure natriuresis curve 
is shifted, is not known but this phenomenon could contribute to 
a deterioration of renal function in acute hemodynamic stresses 
when salt preservation is necessary.
We did not find any change in the resting state norepinephrine 
levels in our patients before or after RDN. Resting state norepinephrine 
taBle 3 | Hemodynamics beforeand after renal denervation at rest and during LBNP.
Variable Period Before lBnP lBnP P  
SBP (mmHg)  M0 154 ± 23 161 ± 20 0.036 
M1 158 ± 23 163 ± 23 0.008 
M12 149 ± 18 151 ± 19 0.320 
Mixed model P = 0.116 
M1 vs. M0 P = 0.348 
M12 vs. M0 P = 0.249 
DBP (mmHg)  M0 85 ± 11 92 ± 11 0.002 
M1 88 ± 13 91 ± 13 0.024 
M12 84 ± 11 86 ± 10 0.069 
Mixed model P = 0.114 
M1 vs. M0 P = 0.157 
M12 vs. M0 P = 0.535 
MBP (mmHg)  M0 108 ± 13 115±11 0.003 
M1 111 ± 14 115±13 0.002 
M12 106 ± 10 108±10 0.097 
mixed model P = 0.136 
M1 vs. M0 P = 0.245 
M12 vs. M0 P = 0.410 
HR (bpm)  M0 58 ± 11 60 ± 9 0.134 
M1 63 ± 11 63 ± 11 0.706 
M12 64 ± 12 63 ± 11 0.453 
mixed model P = 0.030 
M1 vs. M0 P = 0.054 
M12 vs. M0 P = 0.011 
GFR (mL/min)  M0 78 ± 32 67 ± 31 0.011 
M1 79 ± 34 72 ± 31 0.171 
M12 66 ± 26 63 ± 40 0.643 
Mixed model P = 0.012 
M1 vs. M0 P = 0.903 
M12 vs. M0 P = 0.012 
RPF (mL/min)  M0 353 ± 132 297 ± 94 0.039 
M1 380 ± 138 360 ± 149 0.339 
M12 429 ± 76 378 ± 148 0.225 
Mixed model P = 0.127 
M1 vs. M0 P = 0.459 
M12 vs. M0 P = 0.044 
FF (%)  M0 22.6 ± 0.054 22.3 ± 0.058 0.851 
M1 20.9 ± 0.052 21.0 ± 0.056 0.903 
M12 15.1 ± 0.053 16.1 ± 0.062 0.388 
Mixed model P = 0.001 
M1 vs. M0 P = 0.378 
M12 vs. M0 P < 0.001 
RVR (mm Hg/mL/min)  M0 0.222 ± 0.148 0.247 ± 0.086 0.028 
M1 0.195 ± 0.087 0.233 ± 0.144 0.152 
M12 0.145 ± 0.040 0.204 ± 0.14 0.075 
Mixed model P = 0.113 
M1 vs. M0 P = 0.659 
M12 vs. M0 P = 0.045 
Results are mean ± SD or median with interquartiles, SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; HR, heart rate; RPF, renal plasma 
flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR, renal vascular resistance; M0, before renal denervation; M1, 1 month after renal denervation; M12, 12 months after 
renal denervation.
8 May  2018 | Volume 5 | Article 42Frontiers in Cardiovascular Medicine | www. frontiersin. org
Vuignier et al.  Renal Responses After Renal Denervation
levels were not different from healthy volunteers or obese hypertensive 
patients (Figure 2). In contrast, renal norepinephrine spillover was 
reduced in ten patients studied in the SIMPLICITY-1 trial (1, 29). This 
difference could be explained by the limits of measuring peripheral 
norepinephrine, which depend on total regional NE release, 
metabolism, reuptake and clearance. Another possible explanation is 
that the magnitude of RDN was not sufficient to induce an observable 
decrease in peripheral norepinephrine. In this respect, the assessment 
of the procedural success has been at the heart of the debate and 
criticisms that followed the publication of the SYMPLICITY-3 trial 
(30). Interestingly, we found that one year after RDN, the increase in 
norepinephrine induced by LBNP was no longer significant compared 
to resting state values. This finding suggests that the reactivity of the 
SNS is blunted after RDN. It could also explain why BP, especially 
diastolic, measured GFR and RPF were less sensitive to LBNP one 
year after RDN.
The down-regulated RAAS found in our study is in line with 
previous observations, which have suggested that intravascular volume 
is increased in patients with resistant hypertension (31–33). This 
finding is striking since patients were given an angiotensin receptor 
blocker, which could explain a low plasma aldosterone but not a low 
PRA, which should be increased secondary to the interruption of the 
angiotensin II feedback loop. Indeed, PRA was much lower in patients 
with resistant hypertension than in healthy volunteers or in obese 
patients in the same experimental setting (Figure 2). Moreover, PRA 
was not stimulated by LBNP even if a decrease in RBF was observed 
before RDN, which should have increased PRA (34). A low PRA was 
also found in the PATHWAY-2 study despite the use of blockers of 
the renin angiotensin system and diuretics (33). Possible mechanisms 
explaining the suppressed RAS in these patients could be secondary 
Figure 3 |  Resting filtration fraction (FF) before renal denervation (M0), 1 
month (M0) and 12 months (M12) after renal denervation. Data are median, 
interquartile range, minimum and maximum. The small header shows 
individual changes.
taBle 4 | Urinary parametersbefore and after renal denervation at rest and during LBNP.
Variable Period Before lBnP lBnP P 
UV (mL/min)  M0 3.99 ± 1.48 2.81 ± 1.22 0.015 
M1 4.39 ± 1.81 3.04 ± 1.32 0.014 
M12 4.11 ± 1.65 2.62 ± 1.41 0.022 
Mixed model P = 0.742 
M1 vs. M0 P = 0.451 
M12 vs. M0 P = 0.823 
UNaV (µmol/min)  M0 326 ± 138 213 ± 95 0.008 
M1 403 ± 197 291 ± 157 0.046 
M12 285 ± 139 214 ± 127 0.177 
Mixed model P = 0.056 
M1 vs. M0 P = 0.184 
M12 vs. M0 P = 0.285 
Clear Li (ml/min)  M0 22.6 ± 15.8 23.1 ± 15.0 0.902 
M1 19.8 ± 16.3 24.0 ± 15.9 0.127 
M12 11.4 ± 8.7 16.2 ± 15.9 0.122 
Mixed model P = 0.002 
M1 vs. M0 P = 0.284 
M12 vs. M0 P = 0.002 
Results are mean ± SD or median with interquartiles, UV, urine output; UNaV, sodium excretion; Clear Li, endogenous lithium clearance; M0, before renal denervation; M1, 1 month 
after renal denervation; M12, 12 months after renal denervation.
Figure 4 |  Changes in mean blood pressure (MBP) induced by lower body 
negative pressure before RDN (M0), 1 month (M1) and 12 months (M12) after 
renal denervation. Data are median and interquartile range, minimum and 
maximum. The small header shows individual changes.
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ethics stateMent
This study was carried out in accordance with the recommendations 
of the Commission cantonale  d'éthique  de la recherche sur 
l'être humain (http://www. cer- vd. ch). The protocol was approved by 
the Commission cantonale d'éthique de la recherche sur l'être humain. 
All subjects gave written informed consent in accordance with the 
Declaration of Helsinki.
authOr cOntriButiOns
YV: collected data, wrote manuscript. EG: catecholamines 
analysis, revised manuscript. OM: performed RDN, revised 
manuscript. NV: collected data. MF: statistical analysis, 
revised manuscript. SQ: performed RDN, revised manuscript. 
MM: inulin, PAH, endogenous lithium analysis. MB: revised 
manuscript. GW: designed study, collected data, integrity of data, 
analysis of data, wrote the manuscript.
FunDing
This work was supported with grants from the Swiss National 
Science Foundation: PZ00P3_121655, PZ00P3_137262 and 
32003B_149903
acKnOwleDgMents
We thank Dr Narain Moorjani for reading and correcting the 
manuscript.
10 May  2018 | Volume 5 | Article 42Frontiers in Cardiovascular Medicine | www. frontiersin. org
Vuignier et al.  Renal Responses After Renal Denervation
 11. Tidgren B, Hjemdahl P, Theodorsson E, Nussberger J. Renal responses to 
lower body negative pressure in humans. Am J Physiol (1990) 259(4 Pt 
2):F573–9. doi: 10.1152/ajprenal.1990.259.4.F573
 12. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et  al. 
European Society of Hypertension position paper on ambulatory blood 
pressure monitoring. J Hypertens (2013) 31(9):1731–68. doi: 10.1097/
HJH.0b013e328363e964
 13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. 
A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 
(2009) 150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
 14. Magnin JL, Decosterd LA, Centeno C, Burnier M, Diezi J, Biollaz J. 
Determination of trace lithium in biological fluids using graphite furnace 
atomic absorption spectrophotometry: variability of urine matrices 
circumvented by cation exchange solid phase extraction. Pharm Acta Helv 
(1996) 71(4):237–46. doi: 10.1016/S0031-6865(96)00020-9
 15. Dunand M, Gubian D, Stauffer M, Abid K, Grouzmann E. High-throughput 
and sensitive quantitation of plasma catecholamines by ultraperformance 
liquid chromatography-tandem mass spectrometry using a solid phase 
microwell extraction plate. Anal Chem (2013) 85(7):3539–44. doi: 10.1021/
ac4004584
 16. Lenski M, Mahfoud F, Razouk A, Ukena C, Lenski D, Barth C, et  al. 
Orthostatic function after renal sympathetic denervation in patients with 
resistant hypertension. Int  J  Cardiol (2013) 169(6):418–24. doi: 10.1016/j.
ijcard.2013.10.017
 17. Ewen S, Mahfoud F, Linz D, Pöss J, Cremers B, Kindermann I, et al. Effects 
of renal sympathetic denervation on exercise blood pressure, heart rate, 
and capacity in patients with resistant hypertension. Hypertension (2014) 
63(4):839–45. doi: 10.1161/HYPERTENSIONAHA.113.01985
 18. de La Sierra A, Pareja J, Armario P, Barrera Á, Yun S, Vázquez S, et  al. 
Renal denervation vs. spironolactone in resistant hypertension: effects on 
circadian patterns and blood pressure variability. Am J Hypertens (2017) 
30(1):37–41. doi: 10.1093/ajh/hpw085
 19. Ewen S, Dörr O, Ukena C, Linz D, Cremers B, Laufs U, et al. Blood pressure 
variability after catheter-based renal sympathetic denervation in patients 
with resistant hypertension. J Hypertens (2015) 33(12):2512–8. doi: 10.1097/
HJH.0000000000000751
 20. Persu A, Gordin D, Jacobs L, Thijs L, Bots ML, Spiering W. et  al. Blood 
pressure response to renal denervation is correlated with baseline blood 
pressure variability: a patient-level meta-analysis. J Hypertens (2018) 
36(2):221–9. doi: 10.1097/HJH.0000000000001582
 21. Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and 
renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol 
(2013) 8(7):1195–201. doi: 10.2215/CJN.08500812
 22. Hering D, Marusic P, Duval J, Sata Y, Head GA, Denton KM, et  al. Effect 
of renal denervation on kidney function in patients with chronic kidney 
disease. Int J Cardiol (2017) 232:93–7. doi: 10.1016/j.ijcard.2017.01.047
 23. Kiuchi MG, Chen S, Andrea BR, Kiuchi T, Carreira MA, Graciano ML, et al. 
Renal sympathetic denervation in patients with hypertension and chronic 
kidney disease: does improvement in renal function follow blood pressure 
control? J Clin Hypertens (2014) 16(11):794–800. doi: 10.1111/jch.12415
 24. Courand PY, Pereira H, Del Giudice C, Gosse P, Monge M, Bobrie G, 
et  al. Abdominal aortic calcifications influences the systemic and renal 
hemodynamic response to renal denervation in the DENERHTN (renal 
denervation for hypertension) trial. J Am Heart Assoc (2017) 6(10):e007062. 
doi: 10.1161/JAHA.117.007062
 25. Wuerzner G, Chioléro A, Maillard M, Nussberger J, Brunner HR, Burnier 
M, et  al. Angiotensin II receptor blockade prevents acute renal sodium 
retention induced by low levels of orthostatic stress. Kidney Int (2004) 
65(1):238–44. doi: 10.1111/j.1523-1755.2004.00376.x
 26. Singh RR, Sajeesh V, Booth LC, Mcardle Z, May CN, Head GA, et  al. 
Catheter-based renal denervation exacerbates blood pressure fall during 
hemorrhage. J Am Coll Cardiol (2017) 69(8):951–64. doi: 10.1016/j.
jacc.2016.12.014
 27. Vakilzadeh N, Muller ME, Forni V, Milani B, Hoffman L, Piskunowicz M, 
et  al. Comparative effect of a Renin inhibitor and a Thiazide Diuretic on 
renal tissue oxygenation in hypertensive patients. Kidney Blood Press  Res 
(2015) 40(5):542–54. doi: 10.1159/000368530
 28. Bruno RM, Sudano I, Ghiadoni L, Masi L, Taddei S. Interactions between 
sympathetic nervous system and endogenous endothelin in patients with 
essential hypertension. Hypertension (2011) 57(1):79–84. doi: 10.1161/
HYPERTENSIONAHA.110.163584
 29. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-
nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 
361(9):932–4. doi: 10.1056/NEJMc0904179
 30. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et  al. 
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. 
Eur Heart J (2015) 36(4):219–27. doi: 10.1093/eurheartj/ehu441
 31. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, 
Oparil S, et  al. Characterization of resistant hypertension: association 
between resistant hypertension, aldosterone, and persistent intravascular 
volume expansion. Arch Intern Med (2008) 168(11):1159–64. doi: 10.1001/
archinte.168.11.1159
 32. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing 
hemodynamic management to specialist care. Hypertension (2002) 
39(5):982–8. doi: 10.1161/01.HYP.0000016176.16042.2F
 33. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. 
Spironolactone versus placebo, bisoprolol, and doxazosin to determine 
the optimal treatment for drug-resistant hypertension (PATHWAY-2): a 
randomised, double-blind, crossover trial. Lancet (2015) 386(10008):2059–
68. doi: 10.1016/S0140-6736(15)00257-3
 34. Hildebrandt DA, Irwin ED, Cates AW, Lohmeier TE. Regulation of renin 
secretion and arterial pressure during prolonged baroreflex activation: 
influence of salt intake. Hypertension (2014) 64(3):604–9. doi: 10.1161/
HYPERTENSIONAHA.114.03788
 35. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et  al. 
Sequential nephron blockade versus sequential renin-angiotensin system 
blockade in resistant hypertension: a prospective, randomized, open 
blinded endpoint study. J Hypertens (2012) 30(8):1656–64. doi: 10.1097/
HJH.0b013e3283551e98
 36. Herlitz H, Widgren B, Urbanavicius V, Attvall S, Persson B. Stimulatory effect 
of insulin on tubular sodium reabsorption in normotensive subjects with 
a positive family history of hypertension. Nephrol Dial Transplant (1996) 
11(1):47–54. doi: 10.1093/ndt/11.1.47
 37. Kageyama S, Yamamoto J, Isogai Y, Fujita T. Effect of insulin on sodium 
reabsorption in hypertensive patients. Am. J. Hypertens. (1994) 7(5):409–15. 
doi: 10.1093/ajh/7.5.409
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Vuignier, Grouzmann, Muller, Vakilzadeh, Faouzi, Maillard, Qanadli, 
Burnier and Wuerzner. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduction 
in other forums is permitted, provided the original author(s) and the copyright owner 
are credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which does 
not comply with these terms.
